Blossom

Built a massive free database & reports at | ✉️ subscribe to The Bloom for weekly updates | Tweet about psychedelic science & therapy

[Blossom @blossomact]

Find over 1400 psychedelic research papers in our updated database

📣 Filter by topic, from neuroscience to OCD
🥼 Only show the type of study you want to find (e.g. double-blind)
🌵 Get specific about which compound to show

https://t.co/ctl9djYXVf

https://t.co/j1TRKOl0uF

[Blossom @blossomact]

In just over a week, I'll be joining Breaking Convention again. It's the most fun conference in the space, and I'm looking forward to seeing you all there. Get a 10% discount with code BLOSSOM10

[Blossom @blossomact]

I'm eager to hear your thoughts, reactions, and especially your ideas on how we can collaborate to overcome these barriers together.

Let's talk. And let's transform possibilities into realities.

https://t.co/hgnk3yKUqm

[Blossom @blossomact]

I'm excited—and frankly, a little nervous—to share something we've been working on for the last 6 months: our new report on reimbursement pathways for psychedelic therapies in Europe supported by Norrsken Mind.

The full report is linked below 👇

[Blossom @blossomact]

This isn't just about research—it's personal. I believe passionately that psychedelic therapies can revolutionise mental healthcare. And as an industry, we have an obligation to ensure that innovation isn't just possible but accessible and affordable.

[Blossom @blossomact]

This computational fMRI study (n=15) examines brain dynamics after DMT (iv; 20mg) administration, focusing on the onset of the psychedelic state. It reveals a peak destabilization of brain dynamics around 5 minutes post-administration and identifies a heightened reactivity phase, primarily affecting fronto-parietal and visual regions. The study links these changes to serotonin 5HT2a receptor density, suggesting these dynamics underpin the psychedelic state’s complexity and flexibility.
https://t.co/g9T3U3wANX

[Blossom @blossomact]

This randomized, double-blind, cross-over study (n=23) investigates LSD (100μg) effects after daily paroxetine (SSRI) or placebo administration in healthy participants. It finds paroxetine reduced negative LSD effects (“bad drug effect,” “anxiety,” “nausea”) while maintaining pleasant effects, and caused higher LSD concentrations (1.4-1.5x) due to CYP2D6 inhibition, suggesting no LSD dose adjustment is needed when combined with CYP2D6-inhibiting SSRIs.
https://t.co/grEcDZY0u2

[Blossom @blossomact]

This one-year observational follow-up study (n=66) examined the long-term outcomes of psilocybin (25 mg, 10 mg, 1 mg; COMP360) in treatment-resistant depression (TRD). Median time to depressive relapse was longest in the 25 mg group (92 days) compared to 10 mg (83 days) and 1 mg (62 days), with most participants relapsing by week 12. A post hoc analysis of those entering the follow-up study (n=58) found a more pronounced difference, with the 25 mg group maintaining benefits for 189 days. Adverse events were minimal, with one case of mild suicidal ideation in the 1 mg group.
https://t.co/l0nJihieya

[Blossom @blossomact]

This systematic review (s=8) analyses completed controlled trials of psychedelics for depression, including psilocybin, LSD, ayahuasca, and DMT, all in Phase II or I/II. It evaluates methodological patterns against the draft European Medicines Agency guideline revision, highlighting challenges such as unblinding, expectancy, and adverse event characterisation, while calling for larger studies to assess long-term efficacy and safety.
https://t.co/b8HaljRAzZ

[Blossom @blossomact]

This naturalistic longitudinal study (n=66) investigates the long-term effects of ayahuasca on mental health in adults with no prior exposure. Participants attending neo-shamanic ceremonies reported sustained improvements in depression, anxiety, stress, affect, personality traits, spirituality, and relationships up to 12 months. Individuals with depression or anxiety experienced lasting symptom reductions, while those without a diagnosis had short-term benefits. Alcohol and cannabis use decreased only at one month. Findings suggest ayahuasca’s mental health benefits persist, with varying trajectories of change over time.
https://t.co/e7RgieLSTX

[Blossom @blossomact]

This single-blind, cross-over study (n=28) using MRI in healthy participants found that psilocybin (18.2mg/70kg) significantly decreased cerebral blood flow (CBF) and internal carotid artery (ICA) diameter. In contrast, ketanserin (20mg) had no significant effect. This finding suggests an asymmetric 5-HT2AR modulatory effect on CBF and provides the first in vivo human evidence of psilocybin-induced ICA constriction.
https://t.co/dpXOyyR2si

[Blossom @blossomact]

This pre-print, multimodal study (n=18) investigates psilocybin’s (5mg and 10mg) effects on perception and brain dynamics using psychophysics, ultra-high field fMRI, and computational modelling. It finds that psilocybin alters contextual perception in the Ebbinghaus illusion, modifies cortical responses to visual stimuli, and proposes a computational model linking these changes, suggesting altered contextual computations as a potential general mechanism of psychedelic action.
https://t.co/DHAYcjJG5t

[Blossom @blossomact]

This systematic review and meta-analysis (s=87; 2025) finds esketamine’s efficacy as an adjunctive therapy for treatment-resistant depression (TRD) to be modest (effect size 0.15-0.23) and comparable to atypical antipsychotics, with no significant effect on suicidality. The review raises concerns about esketamine’s abuse potential and unknown long-term effects. It also highlights regulatory issues, including deaths and emerging suicidality during clinical trials.
https://t.co/SYTkBoqjHV

[Blossom @blossomact]

This single-blind (n=11) study with healthy participants shows that confidence in negative self-beliefs decreased after a high dose of psilocybin (25mg) which predicted increases in well-being four weeks later. This provides the first psychological (vs neurological) information on the validity of the REBUS model.
https://t.co/ZqKpxlM9B5

[Blossom @blossomact]

This pooled analysis of two Phase II RCTs (n=79) evaluates psilocybin-assisted psychotherapy (PAP/PAT) for cancer-related distress. PAT significantly improves anxiety, depression, interpersonal sensitivity, hostility, obsession–compulsion, and somatization without inducing lasting phobia, paranoia, or psychosis.
https://t.co/3hEmYfNGwf